You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Moodys
AstraZeneca
Baxter
Colorcon

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CT-011


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for CT-011?

CT-011 is an investigational drug.

There have been 12 clinical trials for CT-011. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2007.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Neoplasms, Plasma Cell, and Multiple Myeloma. The leading clinical trial sponsors are CureTech Ltd, Augusta University, and Teva Pharmaceutical Industries.

Recent Clinical Trials for CT-011
TitleSponsorPhase
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaCureTech LtdPhase 1/Phase 2
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaYvonne EfeberaPhase 1/Phase 2
Gemcitabine and CT-011 for Resected Pancreatic CancerAugusta UniversityPhase 2

See all CT-011 clinical trials

Clinical Trial Summary for CT-011

Top disease conditions for CT-011
Top clinical trial sponsors for CT-011

See all CT-011 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Johnson and Johnson
Moodys
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.